Tonix Pharmaceuticals Holding Corp. announced that its management team will participate in two upcoming investor conferences in March 2026. The company's participation in these events provides investors with direct access to leadership during a period of significant commercial and clinical development.
Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach.
This investor outreach comes as Tonix Pharmaceuticals operates as a fully-integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments in areas of high unmet medical need. The company's recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), represents the first new treatment for fibromyalgia in more than 15 years, addressing a significant therapeutic gap for patients suffering from this chronic condition.
The company's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Beyond its commercial products, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder, potentially expanding the treatment's impact across multiple CNS conditions.
Tonix's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease with limited treatment options. The company is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Investor conferences like these provide crucial platforms for biotechnology companies to communicate their progress, strategy, and pipeline potential to the investment community. For Tonix, the timing is particularly significant as the company transitions from a development-stage to a commercial-stage organization with multiple products on the market and additional candidates advancing through clinical trials.
The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. BioMedWire, which distributed the original announcement, is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. More information about BioMedWire is available at https://www.BioMedWire.com.
For investors and industry observers, these conferences offer insight into Tonix's strategic direction, particularly regarding the commercialization of TONMYA and the advancement of its diverse pipeline. The company's focus on CNS and immunology represents areas of growing medical need and commercial opportunity, making its progress relevant to both patient communities and the broader healthcare investment landscape.
